Outlook of therapeutic and diagnostic competency of nanobodies against SARS-CoV-2: A systematic review.

ABSTRACT:

Purpose

The newly emerged coronavirus (SARS-CoV-2) continues to infect humans, and no completely efficient treatment has yet been found. Antibody therapy is one way to control infection caused by COVID-19, but the use of classical antibodies has many disadvantages. Heavy chain antibodies (HCAbs) are single-domain antibodies derived from the Camelidae family. The variable part of these antibodies (Nanobodies or VHH) has interesting properties such as small size, identify criptic epitopes, stability in harsh conditions, good tissue permeability and cost-effective production causing nanobodies have become a good candidate in the treatment and diagnosis of viral infections.

Methods

Totally 157 records (up to November 10, 2021), were recognized to be reviewed in this study. 62 st

SUBMITTER: Aria H 

PROVIDER: S-EPMC8730734 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature